Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Income from Continuing Operations (2019 - 2025)

Burning Rock Biotech has reported Income from Continuing Operations over the past 7 years, most recently at 1949000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 79.87% year-over-year to 1949000.0; the TTM value through Dec 2025 reached 7300525.36, up 84.26%, while the annual FY2025 figure was 7803376.48, 83.57% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 1949000.0 at Burning Rock Biotech, up from 2282152.04 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 1273860.7 in Q2 2025 and troughed at 41184386.88 in Q1 2022.
  • A 5-year average of 20677775.12 and a median of 23306244.46 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 251.04% in 2021 and later surged 91.43% in 2025.
  • Year by year, Income from Continuing Operations stood at 39771000.0 in 2021, then rose by 22.56% to 30798000.0 in 2022, then rose by 26.79% to 22546000.0 in 2023, then soared by 57.06% to 9681000.0 in 2024, then surged by 79.87% to 1949000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BNR at 1949000.0 in Q4 2025, 2282152.04 in Q3 2025, and 1273860.7 in Q2 2025.